While gefitinib + chemo did show a similar PFS as frontline osimertinib, the tolerability and safety profile concerns me. Therefore, I do not plan to change my practice and will still use osimertinib as frontline therapy for my patients with EGFR mutated stage IV lung cancer.

The trial comparing gefitinib to gefitinib and carboplatin + pemetrexed in advanced, treatment naïve EGFR mutated NSCLC presented by Dr. Noronha at ASCO 2019 was performed in a setting where osimertinib is not always accessible for patients. The PFS is clearly better with the combination than with...

There are now 2 trials (one from Japan and one from India) that report the addition of carboplatin plus pemetrexed to gefitinib improves overall survival compared with gefitinib alone in patients with stage IV EGFR mutated non-small cell lung cancer.  For patients who receive their medical care...

No.  Gefitinib is no longer the standard of care for first line EGFR mutant disease.  Osimertinib has significantly better outcomes and less toxicity than either gefitinib or gefitinib plus chemotherapy, and prevents the emergence of brain metastases.  

In the mednet poll most providers voted for Osimertinib  as the preferred  front line which is currently the standard of care in USA, and it makes sense to continue this practice since it is definitely a better drug and has CNS penetration as the experts indicate above. Interestingly, a p...

Combining chemo and TKI has been evaluated previously. Even though recent efficacy data is promising, toxicity is of concern. I do not plan on changing my front line TKI option based on this new data